Search

everythinglearnresearchcommunity

for

Search:↓

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

Ganoderma lucidum may help treat enlarged prostate in rats.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

Serum triglyceride levels are not linked to prostate cancer risk.

Finasteride effectively treats baldness but may cause sexual side effects.

The article concludes that a balance is needed between individual healthcare needs and societal resources when it comes to lifestyle drugs, with a call for compassionate policy application.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Finasteride reduces prostate size and PSA levels in young patients.

PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.

After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Urinary PSA could be an early marker for enlarged prostate.

Estrogen helps prevent artery plaque by stopping monocyte capture in blood vessels.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

A new method was created to test the effectiveness of Dihydrotestosterone (DHT) inhibitors, like finasteride and dutasteride, in human and fish cells. The results showed fish cells are more sensitive to these treatments, and dutasteride works better than finasteride in all tested cells.

Finasteride treats hair loss but may affect prostate cancer detection.

CT scans can find serious prostate cancer even when PSA levels are low.

Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

Finasteride works better for hair loss in patients 26 or younger.